Insmed Incorporated
Every calculator, already run for INSM
Open the full toolkit →You have the numbers on INSM. Get the argument.
A written report on which of these readings actually decide the outcome for Insmed Incorporated, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
24 analysts covering INSMAnalyst Price Target Disagreement for Insmed Incorporated
Wall Street's bull case implies +133% from the current price; the bear case implies +51%. A 81% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for INSM
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Insmed Incorporated
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and…
INSM — frequently asked
Is INSM a buy right now?
Wall Street's consensus rating on Insmed Incorporated is Strong Buy across 24 analysts, with a mean price target of $194.18 (+86% vs. the current $104.44). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for Insmed Incorporated?
Analysts covering Insmed Incorporated (INSM) range from a bear-case target of $158.00 to a bull-case high of $243.00, with a mean consensus target of $194.18 across 22 analysts. The spread of $85.00 (81% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Insmed Incorporated against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Insmed Incorporated
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full INSM research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Insmed Incorporated, in minutes. 3 free reports included with every account — no credit card required.